Free Trial

BioLineRx (BLRX) Competitors

BioLineRx logo
$3.72 +0.06 (+1.64%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$3.73 +0.01 (+0.27%)
As of 10/24/2025 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BLRX vs. ESLA, INKT, NRXP, TVRD, ALGS, CUE, GNTA, ANL, OTLK, and ELYM

Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Estrella Immunopharma (ESLA), MiNK Therapeutics (INKT), NRx Pharmaceuticals (NRXP), Tvardi Therapeutics (TVRD), Aligos Therapeutics (ALGS), Cue Biopharma (CUE), Genenta Science (GNTA), Adlai Nortye (ANL), Oncobiologics (OTLK), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry.

BioLineRx vs. Its Competitors

BioLineRx (NASDAQ:BLRX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Estrella Immunopharma has lower revenue, but higher earnings than BioLineRx. Estrella Immunopharma is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLineRx$28.94M0.56-$9.22M-$8.80-0.42
Estrella ImmunopharmaN/AN/AN/A-$0.30-7.93

BioLineRx currently has a consensus price target of $26.00, suggesting a potential upside of 598.92%. Estrella Immunopharma has a consensus price target of $16.00, suggesting a potential upside of 572.27%. Given BioLineRx's stronger consensus rating and higher possible upside, research analysts clearly believe BioLineRx is more favorable than Estrella Immunopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLineRx
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67
Estrella Immunopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

BioLineRx has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 55.1% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Estrella Immunopharma has a net margin of 0.00% compared to BioLineRx's net margin of -45.34%. BioLineRx's return on equity of -49.74% beat Estrella Immunopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
BioLineRx-45.34% -49.74% -17.54%
Estrella Immunopharma N/A -1,132.38%-358.54%

In the previous week, BioLineRx and BioLineRx both had 2 articles in the media. Estrella Immunopharma's average media sentiment score of 1.91 beat BioLineRx's score of 0.95 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company Overall Sentiment
BioLineRx Positive
Estrella Immunopharma Very Positive

Summary

BioLineRx beats Estrella Immunopharma on 9 of the 13 factors compared between the two stocks.

Get BioLineRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLRX vs. The Competition

MetricBioLineRxMED IndustryMedical SectorNASDAQ Exchange
Market Cap$15.93M$2.97B$6.23B$10.66B
Dividend YieldN/A57.75%5.71%4.82%
P/E Ratio-0.4225.9530.2930.25
Price / Sales0.56782.21595.12134.57
Price / CashN/A168.3237.0161.44
Price / Book0.925.6512.046.60
Net Income-$9.22M$33.06M$3.32B$276.82M
7 Day Performance-0.27%3.15%1.88%2.53%
1 Month Performance-1.85%8.13%7.68%3.71%
1 Year Performance-77.04%-2.49%56.01%33.82%

BioLineRx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BLRX
BioLineRx
2.2293 of 5 stars
$3.72
+1.6%
$26.00
+598.9%
-76.8%$15.93M$28.94M-0.4240Analyst Forecast
ESLA
Estrella Immunopharma
3.0423 of 5 stars
$1.99
+13.7%
$16.00
+704.0%
+179.7%$64.86MN/A-7.65N/ANews Coverage
Positive News
Short Interest ↓
INKT
MiNK Therapeutics
2.8952 of 5 stars
$14.77
+5.5%
$37.50
+153.9%
+106.9%$63.32MN/A-5.1330Positive News
NRXP
NRx Pharmaceuticals
2.7948 of 5 stars
$3.31
+4.1%
$34.50
+942.3%
+160.3%$62.99MN/A-1.482Analyst Forecast
TVRD
Tvardi Therapeutics
2.9593 of 5 stars
$6.17
-6.2%
$55.50
+799.5%
N/A$61.70M$7.14M0.0080
ALGS
Aligos Therapeutics
4.0413 of 5 stars
$10.44
+4.5%
$50.00
+378.9%
+7.3%$61.45M$3.94M-0.5390News Coverage
Analyst Forecast
Gap Up
CUE
Cue Biopharma
2.4651 of 5 stars
$0.82
+3.1%
N/A-49.7%$61.19M$9.29M-1.4760Positive News
Gap Up
GNTA
Genenta Science
1.1557 of 5 stars
$3.20
+0.6%
N/A+15.9%$60.82MN/A0.007News Coverage
Gap Up
ANL
Adlai Nortye
1.2605 of 5 stars
$1.65
+0.6%
$9.00
+445.5%
-21.0%$60.52M$5M0.00127Analyst Forecast
Short Interest ↑
Gap Up
OTLK
Oncobiologics
2.8814 of 5 stars
$1.48
+13.0%
$7.00
+373.0%
-74.0%$58.19MN/A-2.6020Positive News
ELYM
Eliem Therapeutics
N/A$1.93
-1.0%
N/A-57.2%$57.42MN/A-3.649

Related Companies and Tools


This page (NASDAQ:BLRX) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners